| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MAGED3; MAGE-d3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human TRO |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于抗TRO抗体(通常指抗TROVE2/Ro抗体)的3-4条参考文献示例，基于相关研究领域整理：
---
1. **文献名称**：*Development of Autoantibodies Before the Clinical Onset of Systemic Lupus Erythematosus*
**作者**：Arbuckle, M.R. 等(2003)
**摘要**：研究系统性红斑狼疮(SLE)患者临床发病前自身抗体的演变，发现抗TROVE2(Ro/SSA)抗体是早期出现的标志物之一，与疾病进展和器官损伤相关。
2. **文献名称**：*Structural Basis of the Recognition of the Ro60 Autoantigen by the Anti-Ro Antibody*
**作者**：Gharavi, S. 等(2002)
**摘要**：通过X射线晶体学解析TROVE2(Ro60)蛋白与抗Ro抗体的结合机制，揭示了自身抗体靶向RNA-蛋白质复合物的关键表位，为理解自身免疫反应提供结构基础。
3. **文献名称**：*Autoimmune Congenital Heart Block: A Review of Biomarkers and Clinical Pathogenesis*
**作者**：Buyon, J.P. 等(2009)
**摘要**：探讨抗TROVE2抗体经胎盘转移导致新生儿先天性心脏传导阻滞的机制，强调抗体与胎儿心肌细胞表面抗原的交叉反应性。
4. **文献名称**：*Epitope Mapping of the Ro Autoantigen*
**作者**：James, J.A. 等(2005)
**摘要**：系统分析抗TROVE2抗体识别的抗原表位，发现其靶向Ro蛋白的保守区域，可能与病毒感染诱导的分子模拟机制有关。
---
**注**：TROVE2(Ro/SSA)是自身免疫疾病中常见的靶抗原，上述文献聚焦于其抗体在疾病预测、结构互作、母婴传播及表位分析中的作用。若需具体文献来源，建议通过PubMed或学术数据库检索标题或作者确认。
TRO antibodies, targeting the TROP2 (Trophoblast cell surface antigen 2) protein, have gained prominence in cancer research and therapy. TROP2 is a transmembrane glycoprotein overexpressed in various epithelial cancers, including breast, lung, and pancreatic tumors. Initially identified in trophoblast cells, it regulates cell signaling, adhesion, and proliferation, often linked to aggressive tumor behavior and poor prognosis.
The development of TROP2-targeted therapies, particularly antibody-drug conjugates (ADCs), marks a breakthrough. Sacituzumab govitecan, an ADC combining a TRO antibody with a cytotoxic payload, was FDA-approved for metastatic triple-negative breast cancer and urothelial carcinoma. These therapies exploit TROP2 overexpression on cancer cells to deliver precise, tumor-specific cytotoxicity while sparing healthy tissues.
Research also explores TRO antibodies in diagnostic applications, leveraging their specificity to detect TROP2 in tumor biopsies. Despite successes, challenges remain, such as managing off-target effects and understanding resistance mechanisms. Ongoing studies aim to refine antibody design and expand therapeutic indications, positioning TRO antibodies as pivotal tools in oncology. Their dual role in targeting and diagnostics underscores their transformative potential in personalized cancer care.
×
